Your browser doesn't support javascript.
loading
Prognostic Value of the Pretreatment Advanced Lung Cancer Inflammation Index (ALI) in Diffuse Large B Cell Lymphoma Patients Treated with R-CHOP Chemotherapy.
Park, Young Hoon; Yi, Hyeon Gyu; Lee, Moon Hee; Kim, Chul Soo; Lim, Joo Han.
Afiliación
  • Park YH; Department of Hematology/Oncology, Hanil General Hospital, Seoul, Republic of Korea.
Acta Haematol ; 137(2): 76-85, 2017.
Article en En | MEDLINE | ID: mdl-28076862
BACKGROUND: The Advanced Lung Cancer Inflammation Index (ALI, body mass index × albumin/neutrophil-to-lymphocyte ratio) has been demonstrated to be a prognostic factor of survival in some solid cancers. We retrospectively investigated the usefulness of the ALI to predict chemotherapy response and survival in 212 patients with diffuse large B cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy. METHODS: Patients were allocated to a low ALI group (n = 82, 38.7%) or a high ALI group (n = 130, 61.3%) according to an optimal pretreatment ALI cut-off value of 15.5 as determined by receiver operating curve analysis. RESULTS: The low ALI group displayed more adverse clinical characteristics, lower rates of complete remission (54.9 vs. 75.4%, p = 0.008), and poorer 5-year progression-free (PFS, 58.1 vs. 77.3%, p = 0.006) and overall (OS, 64.2 vs. 80.2%, p = 0.008) survival. Multivariate analysis showed that low ALI was found to independently predict shorter PFS and OS. Interestingly, a low ALI reverted to a high ALI during treatment in 58 patients (27.4%), and the 5-year OS of these patients was better than that of patients whose ALI remained low (n = 24, 72.5 vs. 24%, p < 0.001). CONCLUSIONS: ALI might be an easily available marker for predicting clinical outcomes in DLBCL patients treated with R-CHOP chemotherapy.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Linfoma de Células B Grandes Difuso / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Acta Haematol Año: 2017 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Linfoma de Células B Grandes Difuso / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Acta Haematol Año: 2017 Tipo del documento: Article